Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02849977 · ClinicalTrials.gov registry record
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
A clinical trial, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- 5,966
- Enrollment target
NCT02849977: Completed study, sponsored by Rhythm Pharmaceuticals.
NCT02849977 is a clinical trial that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 5,966 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02849977 has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- 5,966 participants
- Enrollment target
Study Summary
The purpose of this screening study is to identify people who have a rare genetic cause of obesity - specifically three genetic variants (a change in the DNA structure) of the POMC, PCSK1 and LepR genes that are currently known to result in obesity. This screening study will not include any investigational drugs. You will be asked to provide a DNA sample and answer some questions about your medical history and hunger.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,966 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2020-06-09 |
What the finished NCT02849977 record still lists
NCT02849977 is an observational study that tracks outcomes without assigning an intervention. Its 5,966 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02849977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02849977 about?
NCT02849977 is a clinical study titled "Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers". The purpose of this screening study is to identify people who have a rare genetic cause of obesity - specifically three genetic variants (a change in the DNA structure) of the POMC, PCSK1 and LepR genes that are currently known to result in obesity. This screening study will not include any investi...
What is the current status of trial NCT02849977?
This trial is currently completed. The enrollment target is 5,966 participants. The study started on 2016-09-28. Estimated completion is 2020-06-09.
Who is sponsoring clinical trial NCT02849977?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06192511 · 5,980 participants · NA
Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening
- NCT03959085 · 5,951 participants · Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI